• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage
  • Life Sciences
  • Research

Proscia & Hamamatsu Partner to Accelerate Scaled Adoption of Digital Pathology

by Jasmine Pennic 03/09/2022 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print
Proscia & Hamamatsu Partner to Accelerate Scaled Adoption of Digital Pathology

What You Should Know:

– Proscia, the leader in digital and computational pathology solutions, and Hamamatsu Photonics K.K., a leading provider of whole slide imaging systems, today announced a collaboration to accelerate digital pathology adoption at an enterprise scale.

– The cooperation agreement increases the availability of the companies’ best-of-breed, unified solution that combines Proscia’s Concentriq® platform and Hamamatsu’s NanoZoomer® series of whole slide scanners to deliver the full promise of pathology’s digital transformation to laboratories.


Accelerating Digital Pathology Adoption

Digital pathology adoption requires laboratories to leverage a diverse and complex ecosystem of hardware and software solutions that play a vital role in pathologists’ workflows. To practice digital pathology at scale and optimize the end-to-end workflow, laboratories are recognizing the need for an open approach focused on broad interoperability to centralize critical data and routine operations. By employing such an approach, laboratories can drive efficiency and obtain a more holistic view of patients, while equipping pathologists with the flexible, adaptable tools needed to meet the clinical and operational needs of both today and tomorrow.

Collaboration Impact

The collaboration expands access to the companies’ existing joint solution for scanning, image management, and AI, building upon its market traction to-date. Together, Hamamatsu’s NanoZoomer scanners and Proscia’s AI-enabled Concentriq platform for image and data management provide a unified solution for the end-to-end pathology workflow, delivering seamless interoperability and enhanced customer experience. Users of Hamamatsu’s scanners can now seamlessly integrate their images and all other data into an open ecosystem centered around Concentriq, enabling leading laboratories to drive day-to-day operations and practice digital pathology at an enterprise scale. Under the cooperation agreement, customers will also receive support with implementation to derive full value from the joint solution.

“This collaboration between Hamamatsu and Proscia will provide a true open ecosystem to the market to increase digital pathology adoption,” said Akiyoshi Mabuchi, Manager Business Planning, Systems Division at Hamamatsu.

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tagged With: AI, data management, Digital Pathology, digital transformation, interoperability, Proscia, Vital

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Insights

2025 EMR Software Pricing Guide

2025 EMR Software Pricing Guide

Featured Interview

Paradigm Shift in Diabetes Care with Studio Clinics: Q&A with Reach7 Founder Chun Yong

Most-Read

Medtronic to Separate Diabetes Business into New Standalone Company

Medtronic to Separate Diabetes Business into New Standalone Company

White House, IBM Partner to Fight COVID-19 Using Supercomputers

HHS Sets Pricing Targets for Trump’s EO on Most-Favored-Nation Drug Pricing

23andMe to Mine Genetic Data for Drug Discovery

Regeneron to Acquire Key 23andMe Assets for $256M, Pledges Continuity of Consumer Genome Services

CureIS Healthcare Sues Epic: Alleges Anti-Competitive Practices & Trade Secret Theft

The Evolving Role of Physician Advisors: Bridging the Gap Between Clinicians and Administrators

The Evolving Physician Advisor: From UM to Value-Based Care & AI

UnitedHealth Group Names Stephen Hemsley CEO as Andrew Witty Steps Down

UnitedHealth CEO Andrew Witty Steps Down, Stephen Hemsley Returns as CEO

Omada Health Files for IPO

Omada Health Files for IPO

Blue Cross Blue Shield of Massachusetts Launches "CloseKnit" Virtual-First Primary Care Option

Blue Cross Blue Shield of Massachusetts Launches “CloseKnit” Virtual-First Primary Care Option

Osteoboost Launches First FDA-Cleared Prescription Wearable Nationwide to Combat Low Bone Density

Osteoboost Launches First FDA-Cleared Prescription Wearable Nationwide to Combat Low Bone Density

2019 MedTech Breakthrough Award Category Winners Announced

MedTech Breakthrough Announces 2025 MedTech Breakthrough Award Winners

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2025. HIT Consultant Media. All Rights Reserved. Privacy Policy |